Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saroglitazar Magnesium in NAFLD/NASH
NCT03061721Phase 2Completed
- Sponsor
- Zydus Therapeutics
- Start
- Apr 2017
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of saroglitazar magnesium in non-alcoholic fatty liver disease (NAFLD) and Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by Zydus Therapeutics. Primary endpoint: Percentage Change From Baseline in Serum Alanine Aminotransferase (ALT) Levels at 16 weeks. Started Apr 2017; status: completed.
02
Drugs
saroglitazar magnesium
03
Conditions
non-alcoholic fatty liver disease (NAFLD)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03061721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03061721.